Compare Danaher Corporation (DHR) vs Garmin Ltd. (GRMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Garmin Ltd. — how do they compare? Danaher Corporation trades at $207.45 (market cap $145.83B), while Garmin Ltd. trades at $309.51 (market cap $59.72B). The key difference: Danaher Corporation is far larger — about 2.4× Garmin Ltd.'s market cap, and Garmin Ltd. pays the higher dividend (1.36%). Which is the better fit depends on your goals.
| DHR | GRMN | |
|---|---|---|
Market Cap | $145.83B | $59.72B |
Sector | Health | Technology |
52-Week High | $242.05 | $313.16 |
52-Week Low | $161.91 | $187.10 |
Enterprise Value | $168.04B | $57.23B |
Dividend Yield | 0.77% | 1.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $209.26, up 2.2% today, with strong technical momentum as the price sits above key support levels. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.92. Fundamentals show robust profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst sentiment is overwhelmingly positive with 69% buy ratings and a $202.33 consensus price target. Recent news highlights the acquisition of Masimo and new product launches in its biotechnology segment.
The outlook for DHR remains favorable driven by earnings beats and strategic acquisitions, but investors face risks from elevated valuation multiples and potential macroeconomic headwinds. The stock's current technical overbought condition suggests near-term consolidation may occur, yet long-term growth prospects in life sciences support a bullish stance. Key watch points include Q3 2026 earnings results and integration progress of recent acquisitions.
Garmin (GRMN) trades at $310.07, near its all-time high, with a slight daily decline of 0.99%. The stock shows strong technical momentum with bullish moving averages, though RSI levels indicate potential overbought conditions. Fundamentally, the company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $2.81 surpassing estimates of $2.30, and raised full-year guidance. Revenue growth remains robust, supported by strength in the fitness segment, while profitability metrics like a 60.08% gross margin highlight operational efficiency.
The outlook for GRMN is positive, driven by sustained demand in wearables and fitness technology, but risks include rich valuation multiples and potential growth deceleration. Analyst consensus is a 'Hold' with a $318.67 price target, suggesting limited near-term upside. Investors should weigh strong execution against premium pricing and competitive pressures in the consumer hardware space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →
